Advances in the study of drug metabolism – symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX)

References

• Aliagas I, Gobbi A, Heffron T, Lee ML, Ortwine DF, Zak M, Khojasteh SC. 2015. A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery. J Comput Aided Mol Des. 29(4):327–328.
   PubMed Web of Science ®Google Scholar
• Bart AG, Scott EE. 2018. Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands. J Biol Chem. 293(50):19201–19210.
   PubMed Web of Science ®Google Scholar
• Bart AG, Takahashi RH, Wang X, Scott EE. 2020. Human cytochrome P450 1A1 adapts active site for atypical nonplanar substrate. Drug Metab Dispos. 48(2):86–92.
   PubMed Web of Science ®Google Scholar
• Bonn B, Leandersson C, Fontaine F, Zamora I. 2010. Enhanced metabolite identification with MS(E) and a semi-automated software for structural elucidation. Rapid Commun Mass Spectrom. 24(21):3127–3128.
   PubMed Web of Science ®Google Scholar
• Broccatelli F, Aliagas I, Zheng H. 2018. Why decreasing lipophilicity alone is often not a reliable strategy for extending IV half-life. ACS Med Chem Lett. 9(6):522–527.
   PubMed Web of Science ®Google Scholar
• Cusack KP, Koolman HF, Lange UE, Peltier HM, Piel I, Vasudevan A. 2013. Emerging technologies for metabolite generation and structural diversification. Bioorg Med Chem Lett. 23(20):5471–5483.
   PubMed Web of Science ®Google Scholar
• Durrant JD, Amaro RE. 2015. Machine-learning techniques applied to antibacterial drug discovery. Chem Biol Drug Des. 85(1):14–21.
   PubMed Web of Science ®Google Scholar
• Fessner ND. 2019. P450 monooxygenases enable rapid late-stage diversification of natural products via C-H bond activation. ChemCatChem. 11(9):2226–2242.
   PubMed Web of Science ®Google Scholar
• Ford KA, Ryslik G, Sodhi J, Halladay J, Diaz D, Dambach D, Masuda M. 2015. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. Drug Metab Rev. 47(3):291–319.
   PubMed Web of Science ®Google Scholar
• Fura A, Shu YZ, Zhu M, Hanson RL, Roongta V, Humphreys WG. 2004. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem. 47(18):4339–4351.
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, Booth BP, Verbois SL, Morse DE, Liang CY, et al. 2007. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 13(5):1367–1373.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 2015. Human cytochrome P540 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450 structure, mechanism, and biochemistry. New York: Kluwer Academic/Plenum; p. 523–785.
   Google Scholar
• Guillemette C, Lévesque É, Rouleau M. 2014. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther. 96(3):324–339.
   PubMed Web of Science ®Google Scholar
• Gumulya Y, Gillam EM. 2017. Exploring the past and the future of protein evolution with ancestral sequence reconstruction: the 'retro' approach to protein engineering. Biochem J. 474(1):1–19.
   PubMedGoogle Scholar
• He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. 1998. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 11(4):252–259.
   PubMed Web of Science ®Google Scholar
• Hunt P, Tyzack J, Segall M. 2018. WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound. J Comput Aided Mol Des. 32(4):537–546.
   PubMed Web of Science ®Google Scholar
• Kirchmair J, Williamson MJ, Tyzack JD, Tan L, Bond PJ, Bender A, Glen RC. 2012. Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. J Chem Inf Model. 52(3):617–648.
   PubMed Web of Science ®Google Scholar
• Lee SK, Xing J, Catlett IM, Adamczyk R, Griffies A, Liu A, Murthy B, Nowak M. 2017. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. Eur J Clin Pharmacol. 73(6):689–698.
   PubMed Web of Science ®Google Scholar
• Li W, Josephs JL, Skiles GL, Humphreys WG. 2008. Metabolite generation via microbial biotransformations with actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and dasatinib. Drug Metab Dispos. 36(4):721–730.
   PubMed Web of Science ®Google Scholar
• Li X, Kamenecka TM, Cameron MD. 2009. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 22(10):1736–1742.
   PubMed Web of Science ®Google Scholar
• Li X, Kamenecka TM, Cameron MD. 2010. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos. 38(7):1238–1245.
   PubMed Web of Science ®Google Scholar
• Lin D, Kostov R, Huang JTJ, Henderson CJ, Wolf CR. 2017. Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 363(1):12–19.
   PubMed Web of Science ®Google Scholar
• Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG. 2007. Pulmonary toxicity associated with erlotinib. Chest. 132(3):1042–1044.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Desai PV, Arimoto R, Desino KE, Fischer H, Keefer CE, Petersson C, Winiwarter S, Broccatelli F. 2017. In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international consortium for innovation through quality in pharmaceutical development. J Med Chem. 60(22):9097–9113.
   PubMed Web of Science ®Google Scholar
• Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL. 2006. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 80(2):136–145.
   PubMed Web of Science ®Google Scholar
• Masood MA, Bazin M, Bunnage ME, Calabrese A, Cox M, Fancy S-A, Farrant E, Pearce DW, Perez M, Hitzel L, et al. 2012. Lead diversification 2: application to P38, gMTP and lead compounds. Bioorg Med Chem Lett. 22:1255–1262.
   Google Scholar
• Obach RS, Walker GS, Sharma R, Jenkinson S, Tran TP, Stepan AF. 2018. Lead diversification at the nanomole scale using liver microsomes and quantitative nuclear magnetic resonance spectroscopy: application to phosphodiesterase 2 inhibitors. J Med Chem. 61(8):3626–3640.
   PubMed Web of Science ®Google Scholar
• Obrezanova O, Segall M. 2010. Gaussian processes for classification: QSAR modeling of ADMET and target activity. J Chem Inf Model. 50(6):1053–1061.
   PubMed Web of Science ®Google Scholar
• Öeren M, Hunt P, Ponting D, Segall M. 2019. Mechanisms and predictions of UGT metabolism. Optibrium Community; [accessed 2019 Sep 20]. http://www.optibrium.com/community/publications/publications-a-presentations/461-mechanismpredictionugt.
   Google Scholar
• Rifaioglu AS, Atas H, Martin MJ, Cetin-Atalay R, Atalay V, Doğan T. 2019. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases. Brief Bioinformatics. 20(5):1878–1912.
   PubMed Web of Science ®Google Scholar
• Sawayama AM, Chen MMY, Kulanthaivel P, Kuo M-S, Hemmerle H, Arnold FH. 2009. A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry. 15(43):11723–11729.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2018-4. Maestro, Schrodinger, LLC. 2018. New York, NY.
   Google Scholar
• Tyzack J, Hunt P, Segall M. 2016. Predicting regioselectivity and lability of cytochrome P450 metabolism using quantum mechanical simulations. J Chem Inf Model. 56(11):2180–2193.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research 2016. Safety testing of drug metabolites: guidance for industry. Silver Spring, MD.
   Google Scholar
• van Santen JA, Jacob G, Singh AL, Aniebok V, Balunas MJ, Bunsko D, Neto FC, Castaño-Espiru L, Chang C, Clark TN, et al. 2019. The natural products atlas: an open access knowledge base for microbial natural products discovery. ACS Cent Sci. 5(11):1824–1833.
   PubMed Web of Science ®Google Scholar
• Walsh AA, Szklarz GD, Scott EE. 2013. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem. 288(18):12932–12943.
   PubMed Web of Science ®Google Scholar
• Walton P, Öeren M, Hunt P, Segall M. 2019. N- and S-oxidation model of the Flavin-containing monooxygenases. Optibrium Community; [accessed 2019 Sep 20]. https://www.optibrium.com/community/publications/publications-a-presentations/450-n-and-s-oxidation.
   Google Scholar
• Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, et al. 2015. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 14(7):475–486.
   PubMed Web of Science ®Google Scholar
• Zamora I, Fontaine F, Serra B, Plasencia G. 2013. High-throughput, computer assisted, specific MetID. A revolution for drug discovery. Drug Discov Today Technol. 10(1):e199–e205.
   PubMedGoogle Scholar
• Zhang RK, Huang X, Arnold FJ. 2019. Selective CH bond functionalization with engineered heme proteins: new tools to generate complexity. Curr Opin Chem Biol. 49:67–75.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li S, Yang Z, Peng Y, Chen X, Zheng J. 2018. Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes. Drug Metab Dispos. 46(4):442–450.
   PubMed Web of Science ®Google Scholar
• Zhao W, Li W, Liu A, Li J, Li P, Tully T, Dai J, Caceres-Cortes J, Traeger S, Burke J, et al. 2017. Characterization of the major metabolites found after plasma metabolite profiling of a BTK inhibitor, BMS-986142, in FIH studies. Poster presented at: 21st North American ISSX Meeting; Sep 24–28; Providence, RI.
   Google Scholar
• Zhao W, Zhang T, Xiao XR, Huang JF, Wang Y, Gonzalez FJ, Li F. 2019. Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. Br J Pharmacol. 176(13):2162–2178.
   PubMed Web of Science ®Google Scholar